Finding that Gpr17 overexpression inhibited oligodendrocyte differentiation and maturation both in vivo and in vitro [224] paved the way for considering GPR17 antagonism as a potential remyelinating strategy in MS. This evidence concerns the gene GPR17 and myeloid sarcoma.